lufepirsen high dose + Vehicle + lufepirsen low dose
Phase 2Recruiting 0 watching 0 views this week⚡ Active
49
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Persistent Corneal Epithelial Defect
Conditions
Persistent Corneal Epithelial Defect
Trial Timeline
Aug 17, 2023 → Dec 1, 2025
NCT ID
NCT05966493About lufepirsen high dose + Vehicle + lufepirsen low dose
lufepirsen high dose + Vehicle + lufepirsen low dose is a phase 2 stage product being developed by Glaukos for Persistent Corneal Epithelial Defect. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05966493. Target conditions include Persistent Corneal Epithelial Defect.
Hype Score Breakdown
Clinical
17
Activity
12
Company
7
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05966493 | Phase 2 | Recruiting |
Competing Products
20 competing products in Persistent Corneal Epithelial Defect